NOBIPROSTOLAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H48O6
Molecular Weight	468.6664
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCC2(CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(=O)OC(C)C)OCCO2

InChI

InChIKey=FCDDMESBMCWDJP-PEEJLGBMSA-N

InChI=1S/C27H48O6/c1-4-5-6-9-12-16-27(31-18-19-32-27)17-15-23-22(24(28)20-25(23)29)13-10-7-8-11-14-26(30)33-21(2)3/h7,10,21-25,28-29H,4-6,8-9,11-20H2,1-3H3/b10-7+/t22-,23-,24+,25-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.walden.co.jp/pdf/4573_r-tech_2015_03_q2_report_2014_12_12_english.pdf | https://adisinsight.springer.com/drugs/800030641 | http://drugprofiles.informa.com/drug_profiles/19985-rk-023 | https://www.prnewswire.com/news-releases/r-tech-ueno-completes-phase-2a-clinical-study-of-rk-023-to-treat-androgenetic-alopecia-114472184.html

Mallinckrodt (previously Sucampo Pharmaceuticals) is developing nobiprostolan (RK 023), a topical therapy for male pattern baldness (androgenetic alopecia) and hypotrichosis. The drug is a physiologically active fatty acid derivative. Nobiprostolan is in Phase IIa clinical trials for the treatment of male pattern baldness.

Originator

Approval Year

Sample Use Guides

In Vivo Use Guide

RK-023 was applied 2 mL each to a hair-thinning part of scalp twice daily in the patients with androgenetic alopecia.

Route of Administration: Topical

Name

Type

Language

NOBIPROSTOLAN

Official Name

English

13,14-DIHYDRO-15,15-ETHYLENEDIOXY-20-ETHYL-PG F2.ALPHA. ISOPROPYL ESTER

Common Name

English

5-HEPTENOIC ACID, 7-(2-(2-(2-HEPTYL-1,3-DIOXOLAN-2-YL)ETHYL)-3,5-DIHYDROXYCYCLOPENTYL)-, 1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.,3.ALPHA.,5.ALPHA.))-

Common Name

English

nobiprostolan [INN]

Common Name

English

PROPAN-2-YL (5E)-7-((1R,2R,3R,5S)-2-(2-(2-HEPTYL-1,3-DIOXOLAN-2-YL)ETHYL)-3,5-DIHYDROXYCYCLOPENTYL(HEPT-5-ENOATE

Systematic Name

English

Code System Code Type Description

NCI_THESAURUS

C166664